Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru

FEDERICO, AUGUSTOVSKI; ARIEL, BARDACH; ADRIÁN, SANTORO; FEDERICO, RODRIGUEZ-CAIROLI; ALEJANDRO, LÓPEZ-OSORNIO; FERNANDO, ARGENTO; MAISSA, HAVELA; ALEJANDRO, BLUMENFELD; JAMILE, BALLIVIAN; GERMÁN, SOLIOZ; ANALÍA, CAPULA; ANALÍA, LÓPEZ; CINTIA, CEJAS; WILLIAM, SAVEDOFF; ALFREDO, PALACIOS; ADOLFO, RUBINSTEIN; ANDRÉS, PICHON-RIVIERE

Cost Effectiveness and Resource Allocation

BioMed Central Ltd

Año: 2023 vol. 21

Objective: Our study analyzes the cost-effectiveness of the COVID-19 vaccination campaigns in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. Methods: Using a previously published SVEIR model, we analyzed the impact of a vaccination campaign (2021) from a national healthcare perspective. The primary outcomes were quality adjusted life years (QALYs) lost and total costs. Other outcomes included COVID-19 cases, hospitalizations, deaths, and life years. We applied a discount rate of 3% for health outcomes. We modeled a realistic vaccination campaign in each country (the realistic country-specific campaign). Additionally, we assessed a standard campaign (similar, “typical“ for all countries), and an optimized campaign (similar in all countries with higher but plausible population coverage). One-way deterministic sensitivity analyses were performed. Findings: Vaccination was health improving as well as cost-saving in almost all countries and scenarios. Our analysis shows that vaccination in this group of countries prevented 573,141 deaths (508,826 standard; 685,442 optimized) and gained 5.07 million QALYs (4.53 standard; 6.03 optimized). Despite the incremental costs of vaccination campaigns, they had a total net cost saving to the health system of US$16.29 billion (US$16.47 standard; US$18.58 optimized). The realistic (base case) vaccination campaign in Chile was the only scenario, which was not cost saving, but it was still highly cost-effective with an ICER of US$22 per QALY gained. Main findings were robust in the sensitivity analyses. Interpretation: The COVID-19 vaccination campaign in seven Latin American and Caribbean countries -that comprise nearly 80% of the region- was beneficial for population health and was also cost-saving or highly cost-effective.